Development and Validation of a Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Phenoxyethanol, Methylparaben, Propylparaben, Mometasone Furoate, and Tazarotene in Topical Pharmaceutical Dosage Formulation

Chinmoy ROY * 1,2, Jitamanyu CHAKRABARTY 2

1 Analytical Research and Development, Integrated Product Development, Dr. Reddy's Laboratories Ltd., Bachupally, Hyderabad-500090, Andhra Pradesh, India.
2 Department of chemistry, National Institute of Technology, Durgapur-713209, West Bengal, India.

* Corresponding author. E-mail: chinmoyanalyst@gmail.com (C. Roy)

Sci Pharm. 2013; 81: 951–967    doi:10.3797/scipharm.1303-22
Published: June 4th 2013    Received: March 26th 2013
Accepted: June 4th 2013

This article is available from: http://dx.doi.org/10.3797/scipharm.1303-22

© Roy and Chakrabarty; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A stability-indicating RP-HPLC method has been developed and validated for the simultaneous determination of phenoxyethanol (PE), methylparaben (MP), propylparaben (PP), mometasone furoate (MF), and tazarotene (TA) in topical pharmaceutical dosage formulation. The desired chromatographic separation was achieved on the Waters X-Bridge™ C18 (50×4.6mm, 3.5µ) column using gradient elution at 256 nm detection wavelength. The optimized mobile phase consisted of 0.1%v/v orthophosphoric acid in water as solvent-A and acetonitrile as solvent-B. The method showed linearity over the range of 5.88–61.76 µg/mL, 0.18–62.36 µg/mL, 0.17–6.26 µg/mL, 0.47–31.22 µg/mL, and 0.44–30.45 µg/mL for PE, MP, PP, MF, and TA, respectively. The recovery for all of the components was in the range of 98-102%. The stability-indicating capability of the developed method was established by analysing the forced degradation samples, in which the spectral purity of PE, MP, PP, MF, and TA along with the separation of degradation products from the analyte peaks was achieved. The proposed method was successfully applied for the quantitative determination of PE, MP, PP, MF, and TA in a cream sample.
Keywords
Mometasone Furoate • Tazarotene • Phenoxyethanol • Parabens • Chromatography • Degradation • RP-HPLC

Introduction
Mometasone furoate (MF), \((11\beta,16\alpha)-9,21\text{-dichloro-11-hydroxy-16-methyl-3,20-dioxo-}\)pregna-1,4-dien-17-yl furan-2-carboxylate (Fig. 1), is a topical corticosteroid; it has anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Mometasone inhibits the action of allergic reactions, eczema, and psoriasis that cause inflammation, redness, and swelling [1, 2].

Tazarotene (TA), ethyl 6-\((4,4\text{-dimethyl-3,4-dihydro-2H-thiochromen-6-yl})\text{ethynyl}\) nicotinate (Fig. 1), is a member of a new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris, and photoaging [3–5]. Psoriasis is one of the most common human skin diseases and is characterized by excessive growth and aberrant differentiation of corneocytes, but is fully reversible with appropriate therapy [6–8].

TA in combination with a mid-potency topical corticosteroid like MF is a valuable first-line treatment option for stable plaque psoriasis. Concurrent use of retinoids and steroids also enhances the speed of efficacy, patient satisfaction, and tolerability [9–11].

The preservative system is an important part of semisolid formulations in preventing the deterioration of formulations from microbial contamination. Methylparaben (MP), propylparaben (PP), and their salts are the most commonly used preservatives and have been used for many years. To establish their effectiveness throughout the shelf life of the product, the actual concentrations of preservatives must be determined, as also required by regulatory agencies [12, 13].

Phenoxyethanol (PE) is a colourless non-allergenic oily liquid that acts as a bactericide and also reduces the need for other preservatives by 10–20-fold.

The finished product released and the shelf life specifications should include an identification test and a content determination test with acceptance criteria and limits for each antimicrobial preservative present in the formulation [14–15]. Hence, their (PE, MP, and PP) antimicrobial and antifungal properties make them an integral part of the product formulation. This encourages the development of a new stability-indicating method for the simultaneous estimation of all the compounds (PE, MP, PP, MF, and TA) to provide the driving force in today’s pharmaceutical industry.

A detailed literature survey for PE, MP, PP, MF, and TA revealed that the determination of each individual compound or in combination with other drugs has been reported using HPLC [1, 2, 11, 13, 16–31], LC-MS [32, 33], electrophoresis [34], and spectrophotometric techniques [35].

The combination of MF and TA is not official in any pharmacopoeia. So far, no reversed-phase liquid chromatography (RPLC) stability-indicating method has been reported for the rapid and simultaneous determination of PE, MP, PP, MF, and TA in topical pharma-
ceutical formulation. Therefore, it is necessary to develop a new rapid and stability-indicating method for the simultaneous determination of five compounds (PE, MP, PP, MF, and TA) in topical pharmaceutical formulation. The proposed method is able to separate PE, MP, PP, MF, and TA from each other and also from the other degradation products. Furthermore, this method was validated according to ICH guidelines [37] and successfully applied for the separation and quantification of all compounds of interest in the topical pharmaceutical formulation. The chemical structures for all of the compounds are presented in Figure 1.

![Chemical Structures](image)

Fig. 1. Chemical Structure of TA, MF, PE, MP, and PP.

**Results and Discussion**

**Method Development and Optimization**

The primary target of the developed HPLC method is to achieve the simultaneous determination of PE, MP, PP, MF, and TA in topical formulations under common chromatographic conditions; those that are applicable to routine quality control of the products in the pharmaceutical and cosmetic industries.

The optimization of column selection and mobile phase selection were done simultaneously. An isocratic method was employed using a buffer (0.02M ammonium acetate pH 2.5 with glacial acetic acid), acetonitrile, and methanol in the ratio of 50:25:25 v/v/v, respectively, as the mobile phase. The X-Terra™ C18 (50×4.6mm, 5µ) column with a flow rate 1.5 mL/min at column temperature 40°C was used in the HPLC, equipped with a photodiode array detector. TA peak fronting was observed and the peak was eluted too late. To reduce the run time and improve the TA peak shape, an attempt was made by replacing methanol with acetonitrile from the mobile phase component which then became 0.02M ammonium acetate (pH 2.5 with glacial acetic acid) and acetonitrile in the ratio of 50:50 v/v. The column was changed to the Waters X-Bridge™ C18 (50×4.6mm, 3.5µ) for better peak shape. The TA peak eluted at 8.0 minutes but the PE and MP peaks were co-
eluting in same retention time in the column void. To separate PE from the MP peak, an attempt was made with gradient elution with the mobile phase (0.02M ammonium acetate pH 2.5 adjusted with glacial acetic acid) as solvent-A and acetonitrile as solvent-B. PE was separated from the MP peak, and also the peak tailing 1.0 was observed for TA. The peak shapes for all of the components were good, but blank interference was observed at the retention time of MF. To remove the blank interference at the retention time of MF, solvent-A was changed to a 0.1%v/v orthophosphoric acid buffer, while keeping acetonitrile as solvent-B with the same gradient mode. As a result, no blank interference was observed. But when the base degradant sample was injected, the MF peak was eluted along with the base degradant peak. To separate the MF peak from the base degradant peak, the gradient programme was modified as time (min)/mobile phase-A (%) /mobile phase-B (%); 0.0/90/10, 1.5/90/10, 4.5/78/22, 8/50/50, 10.5/50/50, 15/5/95, 17/90/10, 20/90/10. While the flow rate was 1.5 mL/min and the column temperature was 50°C, the MF peak was separated from the base degradant peak. Good peak shape for all of the components with well-resolved degradant peaks were observed. Also, the resolution between the PE and MP peak was greater than 2.7. The wavelength was selected by injecting a known concentration of each of PE, MP, PP, MF, and TA into the HPLC with a PDA detector, and was evaluated for the UV spectra of each component. A common wavelength for the simultaneous determination of all the components was selected as 256 nm by overlaying the spectra and wavelength at which all components had significant absorbance.

The extraction of the active components from a semisolid sample matrix with acceptable recovery is a very critical aspect for sample preparation and was achieved by selecting the right diluent in the following manner. Considering the solubility of all the components, the mixture of acetonitrile and water in the ratio of 80:20 (v/v) was used as the diluent and satisfactory recovery was achieved. Based on the above experimental data, the chromatographic separation was finalized by following gradient program time (min)/mobile phase-A (%) /mobile phase-B (%); 0.0/90/10, 1.5/90/10, 4.5/78/22, 8/50/50, 10.5/50/50, 15/5/95, 17/90/10, 20/90/10, at a flow rate of 1.5 mL/min at 50°C (column oven) temperature, detection wavelength 256 nm with 10 µL injection volume. By using the above chromatographic conditions and diluent; the standard, sample, and placebo preparation were made and injected into the HPLC with the developed parameters (Fig. 2).

Analytical Method Validation

After satisfactory development of the method, it was subjected to method validation as per ICH guidelines [36, 37]. The method was validated to demonstrate that it is suitable for its intended purpose by the standard procedure to evaluate adequate validation characteristics (system suitability, accuracy, precision, linearity, limit of detection, limit of quantification, robustness, solution stability, filter compatibility, and stability-indicating capability).

System Suitability

System suitability parameters were measured so as to verify the system, method, and column performance. The system precision was determined by five replicate injections of the standard preparation. Results of the system suitability parameters such as % RSD, theoretical plates, and tailing factor are presented in Table 1.
**Method Precision (Repeatability)**

The precision of the assay method was evaluated by carrying out six independent determinations of 40 µg/mL of PE, 40 µg/mL of MP, 4 µg/mL of PP, 20 µg/mL of MF, and 20 µg/mL of TA in cream samples against qualified working standards. The average % assay (n=6) of PE, MP, PP, MF, and TA were 100.6%, 101.4%, 101.8%, 101.5%, and 98.6%, respectively, with the RSD below 0.7%. Low values of the % RSD indicate that the method is precise (Table 2).

**Intermediate Precision (Reproducibility)**

The purpose of this study is to demonstrate the reliability of the test results with variations. The reproducibility was checked by analyzing the samples by a different analyst using a different chromatographic system and column on a different day. Results are presented in Table 2.

**Specificity**

Specificity is the ability of the method to measure the analyte response in the presence of its potential impurities and placebo matrix [37]. Forced degradation studies were performed to demonstrate the selectivity and stability-indicating capability of the proposed RP-LC method. Figure 2 shows that there is no interference at the retention time of PE, MP, PP, MF, and TA due to the blank or placebo. Overlay chromatograms of the blank, placebo, and standard are presented in Figure 2.

**Tab. 1.** System suitability results (precision, intermediate precision, and robustness) for PE, MP, PP, MF, and TA

|        | Precision | Intermediate Precision | Flow rate 1.7 mL/min | Flow rate 1.3 mL/min | Column temp. 55°C | Column temp. 45°C |
|--------|-----------|-----------------------|----------------------|----------------------|-------------------|-------------------|
| PE     | N>3000    | 4276                  | 3520                 | 3794                 | 5014              | 3355              | 3760              |
|        | T ≤ 2.0   | 1.0                   | 1.0                  | 1.0                  | 1.0               | 1.0               | 1.0               |
|        | R* ≤ 2.0  | 1.2                   | 0.9                  | 0.8                  | 0.5               | 1.1               | 0.4               |
|        | N>5000    | 6866                  | 5723                 | 6366                 | 7846              | 5280              | 5976              |
| MP     | T ≤ 2.0   | 1.0                   | 1.0                  | 1.0                  | 1.0               | 1.0               | 1.0               |
|        | R* ≤ 2.0  | 1.4                   | 0.7                  | 0.3                  | 0.3               | 1.1               | 0.2               |
|        | N>35000   | 60349                 | 57564                | 57290                | 63899             | 47033             | 52952             |
| PP     | T ≤ 2.0   | 1.0                   | 1.0                  | 1.0                  | 1.0               | 1.0               | 1.0               |
|        | R* ≤ 2.0  | 1.1                   | 0.7                  | 0.3                  | 0.6               | 0.2               | 0.9               | 0.2               |
|        | N>50000   | 92610                 | 78964                | 94801                | 84454             | 64779             | 66113             |
| MF     | T ≤ 2.0   | 1.0                   | 1.0                  | 1.0                  | 1.0               | 0.9               | 1.0               |
|        | R* ≤ 2.0  | 1.4                   | 0.7                  | 0.3                  | 0.3               | 0.9               | 0.8               | 0.2               |
|        | N>100000  | 192187                | 179801               | 173149               | 194980            | 152673            | 166620            |
| TA     | T ≤ 2.0   | 1.0                   | 1.0                  | 1.0                  | 1.0               | 1.0               | 1.0               |
|        | R* ≤ 2.0  | 1.4                   | 0.7                  | 0.4                  | 0.3               | 1.0               | 0.4               |

N…USP Plate count; T…USP Tailing factor; R…%Relative standard deviation; temp…Temperature; * Determined on five values.
Tab. 2. Method precision and intermediate precision results

| Comp. | Precision (Day-1) | Intermediate precision (Day-2) |
|-------|------------------|--------------------------------|
|       | Analyst 1 | Analyst 2 | Analyst 1 | Analyst 2 |
| % Assay | % RSD* | % Assay | % RSD* |
| PE   | 100.6 | 0.56 | 100.6 | 1.10 |
| MP   | 101.4 | 0.33 | 100.4 | 0.90 |
| PP   | 101.8 | 0.65 | 101.4 | 0.92 |
| MF   | 101.5 | 0.48 | 101.2 | 1.02 |
| TA   | 98.6 | 0.46 | 98.8 | 0.90 |

*Average of six determinations; **Determined on six values.

Fig. 2. Typical overlay chromatogram of blank and placebo and standard preparation

**Forced Degradation Studies**

Force degradation studies of the drug product were also performed to evaluate the stability-indicating property and specificity of proposed method. Stress studies were performed at the concentration of 40 μg/mL of PE, 40 μg/mL of MP, 4 μg/mL of PP, 20 μg/mL of MF, and 20 μg/mL of TA on the cream formulation. The peak purity test was carried out for the PE, MP, PP, MF, and TA peaks by using a PDA detector on the stress samples. All the solutions used in the forced degradation studies were prepared by dissolving the drug product in a small volume of diluent and further stressing agents. After degradation, these solutions were diluted with diluent to yield the stated PE, MP, PP, MF, and TA concentrations of 40 μg/mL, 40 μg/mL, 4 μg/mL, 20 μg/mL, and 20 μg/mL, respectively.

**Acid Hydrolysis**

Acidic degradation was carried out by adding 1 mL of 0.1N HCl, and after 45 minutes neutralizing the mixture by adding 1 mL 0.1N NaOH. Fig 5 (a) shows significant degradation was observed for MF and one major degradation peak was observed at 10.039 min. Degradation was also observed for TA with a degradation peak at 6.323 min. All the major and minor degradation products were well-separated from the PE, MP, PP, MF, and TA peaks. The peak purity was checked for all five analytes and the results are summarized in Table 3.
Base Hydrolysis

Basic degradation was carried out by adding 0.5 mL of 0.05N NaOH, and after 15 minutes neutralizing the mixture by adding 0.5 mL 0.05 HCl. Fig 5 (b) shows significant degradation was observed for MF and one major degradation peak was observed at 10.036 min. All the degradation products were well-separated from the PE, MP, PP, MF, and TA peaks. The peak purity was checked for all five analytes and the results are summarized in Table 3.

Hydrogen Peroxide Oxidation

Peroxide oxidation was carried out by adding 1 mL of 30%v/v H\textsubscript{2}O\textsubscript{2}, at 70°C for 30 minutes. Fig 5 (c) shows significant degradation for TA was observed when the cream sample was subjected to peroxide oxidation and one main degradation peak was observed at 8.443 min. All the degradation products were well-separated from the PE, MP, PP, MF, and TA peaks. The peak purity was checked for all five analytes and the results are summarized in Table 3.

Thermal Degradation

The cream sample and placebo sample were exposed to dry heat at 75°C for 6 hr. No degradation was observed for thermally exposed samples (75°C, 6hrs).

Photolytic Degradation

The cream sample and placebo samples were exposed to visible light for 240 h resulting in an overall illustration 1.2 million lux h; and UV light for 250 h resulting in an overall illustration 200 w h/m\textsuperscript{2} at 25 °C. Fig 5 (d) shows significant degradation for TA was also observed when the cream sample was subjected to photolytic exposure and one main degradation peak was observed at 8.448 min. Degradation for MF was also observed. All the major and minor degradation products were well-separated from the PE, MP, PP, MF, and TA peaks. The peak purity was checked for all five analytes and the results are summarized in Table 3.

The purity and assay of PE, MP, PP, MF, and TA were unaffected by the presence of its degradation products and thus confirms the stability-indicating power of the developed method. The hypothetical degradation pathways for MF and TA [22] are presented in Fig. 3 and Fig. 4, respectively.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig3.png}
\caption{Hypothetical degradation pathway to MF Impurity-D, (9β,11β,16α)-21-chloro-16-methyl-3,20-dioxo-9,11-epoxypregna-1,4-dien-17-yl furan-2-carboxylate, from MF}
\end{figure}
Fig. 4. Hypothetical degradation pathway to TA Impurity-C, 6-[(4,4-dimethyl-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]nicotinic acid, from TA by acid hydrolysis or base hydrolysis and to TA Impurity-B, ethyl 6-[(4,4-dimethyl-1-oxido-3,4-dihydro-2H-thiochromen-6-yl)ethynyl]pyridine-3-carboxylate, from TA by peroxide oxidation or photolytic exposure

Tab. 3. Results of forced degradation study for PE, MP, PP, MF, and TA

| Comp. | Acidic hydrolysis (0.1 N HCl, RT, 45mins) | Alkaline hydrolysis (0.05 N NaOH, RT, 15mins) | Peroxide oxidation (30% H$_2$O$_2$, RT, 30min) | Thermal exposed (At 75°C, 6h) | Photolytic exposed (1.2 million lux h and 200 wh/m$^2$) |
|-------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------------|-----------------------------------------------|
| PE    | %Deg. ND | 0.195 ND | 0.222 ND | 0.757 ND | 0.191 ND | 0.213 ND |
|       | PA       | 1.288 | 1.274 | 2.234 | 1.230 | 1.273 |
| PTH   |           |          |          |          |          |          |
| MP    | %Deg. ND | 0.085 ND | 0.073 ND | 1.108 ND | 0.067 ND | 0.121 ND |
|       | PA       | 1.095 | 1.086 | 1.174 | 1.091 | 1.139 |
| PTH   |           |          |          |          |          |          |
| PP    | %Deg. ND | 1.188 ND | 0.916 ND | 0.751 ND | 0.661 ND | 0.766 ND |
|       | PA       | 1.887 | 1.633 | 2.148 | 1.607 | 1.967 |
| PTH   |           |          |          |          |          |          |
| MF    | %Deg. 8.5 | 12.6 ND | ND | ND | 15.1 ND |
|       | PA       | 0.339 | 0.666 | 0.289 | 0.285 | 0.486 |
| PTH   | 1.272 | 1.236 | 1.499 | 1.228 | 1.469 |
| TA    | %Deg. 3.7 | 3.7 | 3.7 | ND | 17.6 |
|       | PA       | 0.107 | 0.078 | 0.096 | 0.081 | 0.154 |
| PTH   | 1.124 | 1.119 | 1.155 | 1.116 | 1.233 |

ND...No Degradation; RT...Room temperature; PA...Purity angle; PTH...Purity Threshold.
Fig. 5. A typical overlay chromatogram of (a) acid hydrolysis sample and placebo, (b) base hydrolysis sample and placebo, (c) peroxide oxidation sample and placebo, (d) photolytic light exposed sample and placebo.
Accuracy

The accuracy of an analytical method is the closeness of the test results obtained by that method compared to the true values. To confirm the accuracy of the proposed method, recovery experiments were carried out by the standard addition technique. Three different concentration levels (50%, 100%, and 150%) of standards were added to the pre-analyzed placebo samples in triplicate. The percentage recoveries of PE, MP, PP, MF, and TA at each level and each replicate were determined. The mean of the percentage recoveries (n = 3) and the % RSD were calculated. The amount recovered was within ±1% of the amount added, which indicates that the method is accurate and that there is no interference due to the excipients present in the cream sample. The results of recoveries for the assay are shown in Table 4.

| Comp. | % Recovery # | At 50% | At 100% | At 150% |
|-------|--------------|--------|---------|---------|
| PE    | % R.S.D.*    |        |         |         |
| MP    | % R.S.D.*    |        |         |         |
| PP    | % R.S.D.*    |        |         |         |
| MF    | % R.S.D.*    |        |         |         |
| TA    | % R.S.D.*    |        |         |         |  

Table 4. Accuracy results

*...Determined on three values; #...Mean of three determinations.

Limit of Detection (LOD) and Quantification (LOQ)

The LOD and LOQ were determined at a signal-to-noise ratio of 3:1 and 10:1, respectively, by injecting a series of dilute solutions with known concentrations. The limit of detection and limit of quantification values of PE, MP, PP, MF, and TA are reported in Table 5. The limit of quantification chromatogram is presented in Figure 6.

Fig. 6. Typical chromatogram of LOQ
**Linearity**

The linearity of an analytical method is its ability to elicit test results that are directly, or by a well-defined mathematical transformation, proportional to the concentration of the analyte. Linearity was demonstrated from the LOQ % to 150% of the standard concentration using a minimum of six calibration levels of the test concentration (LOQ-61.76 µg/mL for PE, LOQ-62.36 µg/mL for MP, LOQ-6.26 µg/mL for PP, LOQ-31.22 µg/mL for MF, and LOQ-30.45 µg/mL for TA), which gave us a good confidence on the analytical method with respect to linear range. The response was found to be linear for all PE, MP, PP, MF, and TA from the LOQ to 150% of the standard concentration. The correlation coefficient was also found to be greater than 0.9995. Bias was also found to be within ±0.32. The result of the correlation coefficients, Y-intercept of the calibration curve, and % bias at 100% response for PE, MP, PP, MF, and TA are presented in Table 5.

**Tab. 5.** Evaluation of LOD, LOQ, and linearity data

| Parameter                        | PE     | MP     | PP     | MF     | TA     |
|----------------------------------|--------|--------|--------|--------|--------|
| LOD (µg/mL)                      | 1.764  | 0.054  | 0.051  | 0.140  | 0.132  |
| LOQ (µg/mL)                      | 5.88   | 0.18   | 0.17   | 0.47   | 0.44   |
| Linearity range (µg/mL)          | 5.88–61.76 | 0.18–62.36 | 0.17–6.26 | 0.47–31.22 | 0.44–30.45 |
| Correlation coefficient          | 0.9997 | 0.9999 | 0.9999 | 0.9999 | 0.9999 |
| Intercept (a)                    | 216.992| 276.567| -349.533| 90.771 | -569.537|
| Slope (b)                        | 1730.336| 39762.69576 | 35039.13 | 17737.78 | 16789.99 |
| Bias at 100% response            | 0.307  | 0.017  | -0.241 | 0.025  | -0.168 |

**Robustness**

Robustness, as a measure of the method's capacity to remain unaffected by small, deliberate changes in chromatographic conditions, was studied by testing the influence of small changes in flow rate (1.5 ± 0.2 mL/min) and a change in the column oven temperature (50 ± 5°C). In system suitability parameters such as theoretical plates, tailing factor, and % RSD of PE, MP, PP, MF, and TA standard were studied. In all of the deliberately varied chromatographic conditions, the system suitability parameters met the acceptance criteria. Thus, the method was found to be robust with respect to the variability in the applied conditions. The results are presented in Table 1 along with the system suitability parameters of the precision and intermediate precision study. The resolution between the PE and MP peaks was observed as more than 2.4 for the robustness parameters. Thus, the method was found to be robust with respect to variability in the above conditions.

**Stability of Analytical Solutions**

The stability of the sample solution was established by storage of sample solution at ambient temperature for 24 h. The cream sample solution was re-analyzed after 12- and 24-h time intervals and the assay was determined and compared against the freshly prepared standard solutions. The variability in the assay of all five substances was within ±
1% during solution stability. The results from the solution stability experiments confirmed that the sample solution was stable for up to 24 h during assay determination which are presented in Table 6.

Tab. 6. Solution stability results

| % Assay | Initial | After 12 hrs. | After 24 hrs. |
|---------|---------|---------------|---------------|
| PE      | 100.6   | 100.1         | 100.5         |
| MP      | 101.4   | 101.2         | 100.6         |
| PP      | 101.8   | 101.7         | 100.9         |
| MF      | 101.5   | 101.9         | 101.4         |
| TA      | 98.6    | 98.5          | 98.0          |

Filter Compatibility

Filter compatibility was performed for the nylon 0.22 µm syringe filter (Millipore) and PVDF 0.22 µm syringe filter (Millipore). To confirm the filter compatibility in the proposed method, a filtration recovery experiment was carried out by the sample filtration technique. The sample was filtered through both syringe filters and the percentage assay was determined and compared against the centrifuged sample. The sample solution did not show any significant changes in the assay percentage with respect to the centrifuged sample. Percentage assay results are presented in Table 7. The displayed result difference in % assay was not observed to be more than ±1.0, which indicates that both syringe filters have a good compatibility with sample solution.

Tab. 7. Filter compatibility results

| % Assay | Centrifuged Sample | PVDF filter 0.2µm | Nylon filter 0.2µm |
|---------|-------------------|-------------------|-------------------|
| PE      | 98.6              | 98.5              | 99.2              |
| MP      | 101.2             | 100.7             | 101.6             |
| PP      | 101.9             | 101.2             | 101.8             |
| MF      | 101.9             | 101.3             | 101.5             |
| TA      | 98.5              | 98.0              | 98.7              |

Experimental

Chemicals, Reagents, and Samples

The cream sample, placebo matrix, and working standards were provided by Dr. Reddys Lab, India. HPLC grade acetonitrile and orthophosphoric acid were used (Rankem, Delhi, India). The nylon membrane filter (0.22µm), PVDF syringe filter (0.22µm), and nylon syringe filter (0.22µm) were from Millipore, Mumbai, India. Water for HPLC was generated using the Milli-Q Plus water purification system (Millipore, Milford, MA, USA).

Equipment

The chromatographic analysis was performed using HPLC (Waters 2695 Alliance Separation Module) (Waters Milford, USA) equipped with a PDA detector, quaternary
solvent manager, and autosampler system. The output signals were monitored and processed using Empower 2 software. A Cintex digital water bath was used for the hydrolysis studies. Photostability studies were carried out in photostability chamber (SUN TEST XLS+, Atlas, USA). Thermal stability studies were performed in a dry air oven (Cintex, Mumbai, India).

**Chromatographic Conditions**

All chromatographic experiments were performed using the Waters X-Bridge™ C18 (50×4.6 mm, 3.5µ) column. The optimized mobile phase consisted of 0.1% v/v orthophosphoric acid in water as solvent-A and acetonitrile as solvent-B. Solvents-A and -B were filtered through a 0.22 µm nylon membrane filter and degassed under vacuum prior to use. The separation of PE, MP, PP, MF, TA, and all impurities was achieved by gradient elution using solvent-A and solvent-B. A mixture of acetonitrile and water in the ratio of 80:20 (v/v), respectively, was used as diluent. A gradient program was used as time (min)/mobile phase-A (%)mobile phase-B (%); 0.0/90/10, 1.5/90/10, 4.5/78/22, 8/50/50, 10.5/50/50, 15/5/95, 17/90/10, 20/90/10, at a flow rate 1.5 mL/min at 50°C, detection wavelength 256 nm.

**Standard Solution Preparation**

The stock solutions of PE (400 µg/mL), MP (400 µg/mL), PP (400 µg/mL), MF (200 µg/mL), and TA (200 µg/mL) were prepared by dissolving an appropriate amount of standard substances in diluent, separately. Working standard solution was prepared by mixing the above stock solutions of PE, MP, PP, MF, and TA with a final concentration of 40 µg/mL, 40 µg/mL, 4 µg/mL, 20 µg/mL, and 20 µg/mL, respectively.

**Sample Solution Preparation**

An accurately weighed 1 g sample (equivalent to 1 mg of TA, 1 mg of MF) was taken into a 50 mL volumetric flask. About 35 mL of the mixture of acetonitrile and water (80:20, %v/v) was added to this volumetric flask and sonicated in an ultrasonic bath for 15 min with intermittent shaking, diluted to the volume with a mixture of acetonitrile and water (80:20, %v/v), and mixed well. A portion of the solution was filtered through a 0.22 µm nylon syringe filter and the filtrate was collected after discarding the first few milliliters.

**Placebo (Other Substances Without PE, MP, PP, MF, and TA) Solution Preparation**

An accurately weighed 1 g of the placebo sample was taken into a 50 mL volumetric flask. About 35 mL mixture of acetonitrile and water (80:20, %v/v) was added to this volumetric flask and sonicated in an ultrasonic bath for 15 min with intermittent shaking, diluted to the volume with mixture of acetonitrile and water (80:20, %v/v), and mixed well. A portion of solution was filtered through 0.22 µm nylon syringe filter and the filtrate was collected after discarding first few milliliters.

**Conclusion**

A gradient RP-HPLC method was successfully developed for the simultaneous determination of phenoxyethanol, methylparaben, propylparaben, mometasone furoate, and tazarotene in topical pharmaceutical dosage form. The method validation results have proven that the method is selective, precise, accurate, linear, robust, filter–compatible, and
stability-indicating. Forced degradation data proved that the method is specific for the analytes and free from the interference of the placebo / known impurities / and degradation products. The run time (20.0 min) enables rapid determination of the drug. Moreover, it may be applied for the individual and simultaneous determination of phenoxethanol, methylparaben, propylparaben, mometasone furoate, and tazarotene in the study of content uniformity, tube homogeneity, and invitro release test profiling of mometasone furoate and tazarotene topical pharmaceutical dosage forms, where the sample load is higher and the high throughput is essential for the faster delivery of results.

Acknowledgement

The authors would like to thank M/s Dr. Reddy’s Laboratories Ltd. for supporting this work. Authors wish to acknowledge the formulation development group for providing the samples for our research. The authors’ Intellectual Property Management department (IPM) has given this manuscript internal publication number PUB00231-13.

Authors’ Statement

Competing Interests

The authors declare no conflict of interest.

References

[1] Srinivasarao K, Gorule V, Venkata RC, Venkata KA.
A Validated method development for estimation of formoterol fumarate and mometasone furoate in metered dose inhalation form HPLC.
J Anal Bioanal Techn. 2012; 3: 1–4.
http://dx.doi.org/10.4172/2155-9872.1000153

[2] Shaikh S, Muneera MS, Thusleem OA, Tahir M, Kondaguli AV.
RP-HPLC Method for the Simultaneous Quantitation of Chlorocresol, Mometasone Furoate and Fusidic Acid in Creams.
J Chromatogr Sci. 2009; 47:178–183.
http://dx.doi.org/10.1093/chromsci/47.2.178

[3] Brenna E, Frigoli S, Fronza G, Fuganti C, Serra S.
Impurities of tazarotene: Isolation and structural characterization.
J Pharm Biomed Anal. 2008; 6: 574–576.
http://dx.doi.org/10.1016/j.jpba.2007.11.004

[4] Multum C.
Tazarotene topical.
Drugs.com. 2009; Version: 3.04.

[5] http://www.rxlist.com/tazorac-cream-drug.htm, 2012

[6] Su YH, Fang JY.
Drug delivery and formulations for the topical treatment of psoriasis.
Expert Opin Drug Deliv. 2008; 5: 235–249.
http://dx.doi.org/10.1517/17425247.5.2.235

[7] Meetings and Congresses Complete Doctor’s Guide.
Tazarotene Is First New Generation Retinoid For Treating Plaque Psoriasis. 1997.
[8] Tapash K, Ghosh T. Clinical Pharmacology and Biopharmaceutics Presentation for Oral Tazarotene (NDA 21-701). Office of Clinical Pharm Biopharm.CDER, FDA. 2004.

[9] Poulin YP. Tazarotene 0.1% gel in combination with Mometasone furoate cream in plaque psoriasis: a photographic tracking study. Cutis. 1999; 63: 41–48. http://www.ncbi.nlm.nih.gov/pubmed/9951595

[10] Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000; 22: 1225–1238. http://dx.doi.org/10.1016/S0149-2918(00)83065-9

[11] Shabir GA. Development and validation of a stability-indicating LC method for the determination of domperidone, sorbic acid and propylparaben in pharmaceutical formulations. J Liq Chromatogr Rel Technol. 2010; 33: 1802–1813. http://dx.doi.org/10.1080/10826076.2010.532702

[12] Kuak KL, Hsieh YZ. Determination of preservatives in food-products by cyclodextrin-modified capillary electrophoresis with multiwavelength detection. J Chromatogr A. 1997; 768: 334–341. http://dx.doi.org/10.1016/S0021-9673(97)00040-X

[13] Boonleang J, Tanthana C. Simultaneous stability-indicating HPLC method for the determination of cisapride, methylparaben and propylparaben in oral suspension. Songklanakarin J Sci Technol. 2010; 32: 379–385.

[14] European Medicines Agency. Guideline on Excipients in the Dossier for Application for Marketing Authorisation of a Medicinal Product, Doc. Ref. EMEA/CHMP/QWP/396951/2006, London, 6 November 2006.

[15] International Conference on Harmonization. ICH Q6A; Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances, 1999.

[16] Wang Z, Zhang H, Liu O, Donovan B. Development of an orthogonal SFC method for mometasone furoate impurity analysis. The 5th International Conference on SFC; 2011.

[17] Teng XW, Foe K, Brown KF, Cutler DJ, Davies NM. HPLC analysis of mometasone furoate and its degradation products: application to in vitro degradation studies. J Pharm Biomed Anal. 2001; 26: 313–319. http://dx.doi.org/10.1016/S0731-7085(01)00408-3

[18] Zhu J, Coscolluella C. Chromatographic assay of pharmaceutical compounds under column overloading. J Chromatogr B Biomed Sci. 2000; 741: 55–65. http://www.ncbi.nlm.nih.gov/pubmed/10839132

[19] Donovan JC, Dekoven JG. Cross-reactions to desoximetasone and mometasone furoate in a patient with multiple topical corticosteroid allergies. Dermatitis. 2006; 17: 147–151. http://dx.doi.org/10.2310/6620.2006.05053
[20] Korting HC, Maslen K, Gross G, Willers C. [Comparison of activity of different topical corticosteroid creams and ointments using a vasoconstriction assay: Superiority of hydrocortisone butyrate over hydrocortisone]. J Dtsch Dermatol Ges. 2005; 3: 348–353. http://www.ncbi.nlm.nih.gov/pubmed/16372801

[21] Shaikh KA, Patil AT. Stability-Indicating HPLC Method for the Determination of Mometasone Furoate, Oxymetazoline, Phenyl Ethanol and Benzalkonium Chloride in Nasal Spray Solution. J Trace Anal Food Drugs. 2013; 1: 14–21. http://dx.doi.org/10.7756/jtafd.2013.1002

[22] Roy C, Patel HB, Chakrabarty J. Stability Indicating rp-hplc Method Development and Validation for Determination of Process Related Impurities and Degradation Products of Tazarotene in Tazarotene Topical Formulation. Indo Amer J Pharm Res. 2012; 3: 1400–1413.

[23] Mrunali RP, Rashmin BP, Jolly RP, Bharat GP. HPTLC method for estimation of tazarotene in topical gel formulations and in vitro study. Anal Methods. 2010; 2: 275–281. http://dx.doi.org/10.1039/B9AY00240E

[24] Ahmed SS, Hany WD, Amr MB, Abd EAB, Abd EA. Stability-indicating chemometric methods for the determination of tazarotene. Drug Testing Anal. 2010; 2: 357–361. http://dx.doi.org/10.1002/dta.138

[25] Pathare DB, Jadhav AS, Shingare MS. A Validated Stability Indicating RPLC Method for Tazarotene. Chromatographia. 2007; 66: 247–250. http://dx.doi.org/10.1365/s10337-007-0265-z

[26] Badawy AM, Abd El-AlimAbd El-Aziz B, Saad AS. Stability-indicating spectrophotometric methods for determination of tazarotene in the presence of its alkaline degradation product by derivative spectrophotometric techniques. Drug Testing Anal. 2010; 2: 130–136. http://dx.doi.org/10.1002/dta.109

[27] Attar M, Yu D, Ni J, Yu Z, Ling KH, Tang-Liu DD. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans. J Pharm Sci. 2005; 94: 2246–2255. http://dx.doi.org/10.1002/jps.20427

[28] Madhu C, Duff S, Baumgarten V, Rix P, Small D, Tang-Liu D. Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. J Pharm Sci. 1997; 86: 972–974. http://dx.doi.org/10.1021/js9700558

[29] http://shodhganga.inflibnet.ac.in/bitstream/10603/3456/13/13_chapter%206.pdf

[30] Shabir GA. A New Validated HPLC Method for the Simultaneous Determination of 2-phenoxyethanol, Methylparaben, Ethylparaben and Propylparaben in a Pharmaceutical Gel. Ind J PharmSci. 2010; 72: 421–425. http://dx.doi.org/10.4103/0250-474X.73906

[31] Borremans M, Loco JV, Roos P, Goeyens L. Validation of HPLC Analysis of 2-Phenoxyethanol, 1-Phenoxypropan-2-ol, Methyl, Ethyl, Propyl, Butyl and Benzyl 4-Hydroxybenzoate (Parabens) in Cosmetic Products, with Emphasis on Decision Limit and Detection Capability. Chromatographia. 2004; 59: 47–53. http://dx.doi.org/10.1365/s10337-003-0127-2

Sci Pharm. 2013; 81: 951–967
[32] Sahasranaman S, Tang Y, Biniasz D, Hochhaus GA. A sensitive LCMS method for the quantification of mometasone furoate in human plasma. J Chromatogr B. 2005; 819: 175–179. http://dx.doi.org/10.1016/j.jchromb.2005.01.018

[33] Chen G, Pramanik BN, Liu YH, Mirza UA. Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery. J Mass Spectrom. 2007; 42: 279–287. http://dx.doi.org/10.1002/jms.1184

[34] Kuang LK, You-Zung H. Determination of Preservatives in Food Products by Cyclodextrin-Modified Capillary Electrophoresis with Multiwavelength Detection. J Chromatogr A. 1997; 768: 334–341. http://dx.doi.org/10.1016/S0021-9673(97)00040-X

[35] Ayad MM, EL-Henawee MM, Abdellatef HE, EL, Sayed HM. 24-spectrophotometric determination of levonorgestrel, norethisterone acetate, mometasone furoate and fluticasone propionate using 4-amino-antipyrine. Cairo Bull. 2005; 43: 24–8.

[36] International Conference on Harmonization. ICH Q1A (R2). Stability Testing of New Drug Substances and Products. Geneva, 2000.

[37] International Conference on Harmonization. ICH Q2 (R1). Validation of Analytical Procedures: Text and Methodology, 2005.